SolAeroMed is the leader in biophysical respiratory drugs.

Learn More


Cystic Fibrosis, Asthma Rescue Drug & other chronic obstructive lung diseases In Phase II Clinical Trials


Surfactant Dysfunction In Pre-Clinical Development


About SolAeroMed

SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.


SolAeroMed is attending JP Morgan biotech conference in San Francisco Jan 13-18 2020. Contact CEO Dr John Dennis to arrange a call or meeting:

SolAeroMed is seeking development partners for their novel Cystic Fibrosis, Asthma and Surfactant Dysfunction products.

Learn More